Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Paul G Mariani, MD, Sanford Health, Fargo, ND; Connie S. Price, MD, Denver Health, Denver, CO; Robert Orenstein, DO, Mayo Clinic, Phoenix, AZ; Hill Harris, MD, MPH, Denver Health, Denver, CO; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN

Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antibiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

Download this presentation (356 KB)
Download the abstract (339 KB)

Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA

Background

Fecal transplant is a promising non-antibiotic treatment option for refractory/recurrent Clostridium difficile infection and is gaining increasing acceptance. However, the optimal protocol for fecal transplant is yet to be determined. We report on enema administration of RBX2660 (microbiota suspension), a next generation fecal transplant, for the treatment of recurrent Clostridium difficile infection, with or without antibiotic pre-treatment in the context of the PUNCH CD phase 2 safety study.